SCHEMBL10275883

SCHEMBL10275883

Cc1nn2c(=O)c(-c3ccccc3)c(O)[nH]c2c1-c1ccc(Cl)cc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 4/20 0.43
ARF6 P62330 5/20 0.42
HSD11B1 P28845 1/20 0.41
KDM4E B2RXH2 1/20 0.40
MAPK1 P28482 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39
DPP4 P27487 3/20 0.39
CYP3A4 P08684 2/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 1/20 0.39
TP53 P04637 1/20 0.39
DPP8 Q6V1X1 1/20 0.38
DPP9 Q86TI2 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10275365 0.79 HCRTR1 (0.41) CRHR1ARF6HSD11B1KDM4EMAPK1
SCHEMBL10276175 0.78 MAPT (0.44) CRHR1KDM4EMAPK1MAPTDPP4
SCHEMBL12826181 0.75 CRHR1 (0.44) CRHR1HSD11B1KDM4ENPC1
SCHEMBL5826578 0.74 MEN1 (0.42) CRHR1MEN1KMT2AGAADPP4
SCHEMBL27949767 0.73 ARF6 (0.47) CRHR1ARF6HSD11B1KDM4EMAPK1
SCHEMBL15466871 0.73 CRHR1 (0.55) CRHR1HSD11B1KDM4ETP53
SCHEMBL12826214 0.72 CRHR1 (0.37) CRHR1ARF6KDM4EMEN1KMT2A
SCHEMBL10275796 0.71 CYP3A4 (0.41) CRHR1ARF6KDM4EMEN1KMT2A
SCHEMBL10276006 0.71 ARF6 (0.40) CRHR1ARF6HSD11B1HTTDPP4
SCHEMBL10275556 0.71 SRD5A2 (0.40) CRHR1ARF6KDM4EMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF XU LIFENG (US) 2012-07-12 US claimed
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF XU LIFENG (US) 2012-07-12 US disclosed
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF XU LIFENG (US) 2012-07-12 US disclosed
WO-2011035518-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF 辽宁利锋科技开发有限公司 (CN) 2011-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF TYMP, TYMS, ADORA3 CRHR1 1464/4885ARF6 3355/4885HSD11B1 831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.